Eisai posts long-term data for Leqembi in extended Alzheimer’s study

Eisai (TYO: 4523) has released new 48-month data from a post-hoc analysis of its Clarity AD open-label extension, focusing on adults with early Alzheimer’s disease who are APOE ε4 non-carriers or heterozygotes. The update was presented at the German Society of Neurology meeting in Berlin.

Patients treated continuously with Leqembi (lecanemab) maintained a clear separation from the ADNI observational cohort, showing a 1.53-point difference in adjusted CDR-SB change from baseline. A slope analysis indicated that disease progression was delayed by nearly ten months compared to ADNI participants.

Eisai said the risk of progressing to the next disease stage fell by 32% over four years. No new safety issues emerged for APOE ε4 non-carriers or heterozygotes, the group for which the medicine is authorised in the EU and UK.